Company: INTS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001567264-25-000039
Chunk: 15

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
3,394 4,743 Loss from operations(3,394)(4,743)Other income (expense):Interest income15 140 Other income, net32 - Net loss$(3,347)$(4,603)Loss per share, basic and diluted$(0.22)$(0.34)Weighted average number of shares of common stock, basic and diluted15,173,19613,709,487

The accompanying notes are an integral part of these condensed financial statements.

2

Table of Contents

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(Unaudited)

Common StockAdditional Paid in CapitalAccumulated DeficitStockholders’ EquitySharesAmount Balances at December 31, 202415,122,873$2 $69,699 $(66,783)$2,918  Issuance of common stock in ATM offering, net of $17 issuance costs 141,996- 328 - 328  Stock-based compensation expense -- 435 - 435  Net loss -- - (3,347)(3,347) Balances at March 31, 202515,264,869$2 $70,462 $(70,130)$334 

Common StockAdditional Paid in CapitalAccumulated DeficitStockholders’ EquitySharesAmount Balances at December 31, 202313,709,377$1 $63,676 $(50,515)$13,162  Exercise of warrants2,500- 8 - 8  Stock-based compensation expense -- 1,155 - 1,155  Net loss -- - (4,603)(4,603) Balances at March 31, 202413,711,877$1 $64,839 $(55,118)$9,722 

The accompanying notes are an integral part of these condensed financial statements.

3

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

Three Months Ended March 31,20252024Cash flows from operating activities:Net loss$(3,347)$(4,603)Adjustments to reconcile net loss to net cash used in operating activities:Change in carrying value of right-of-use